SURPASS-CVOT: Tirzepatide Clears Its Cardiovascular Bar Against an Active Comparator (2025)

Tirzepatide's last major evidence question — cardiovascular outcomes — got its answer in 2025 when SURPASS-CVOT reported: in a large population with type 2 diabetes and established cardiovascular disease, tirzepatide was compared not against placebo but against dulaglutide, itself a proven cardioprotective GLP-1, and met its mark with a hazard ratio around 0.92 for major adverse cardiovascular events.

The design detail is the story. Beating placebo is table stakes; matching-to-beating an active cardioprotective comparator in a high-risk population is a stronger statement, and it removed the "great for weight, unproven for hearts" asterisk from the efficacy leader — in diabetes. The precise distinction that survives: semaglutide's SELECT trial still holds the class's only dedicated cardiovascular-outcomes win in people with obesity without diabetes, which is why Wegovy's risk-reduction indication remains a coverage door tirzepatide can't yet open.

For buyers, the practical translation is in our insurance guide: indication side doors are molecule-specific, and the trial map — SURMOUNT for weight, SURPASS-CVOT and SELECT for hearts — is what your prior-authorization paperwork is actually navigating.